Dynamic change of serum FGF21 levels in response to glucose challenge in human

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 7, 2012, Pages

  Lin, Zhuofeng ^a,b   Gong, Qi ^a   Wu, Chaoming ^a   Yu, Jiawen ^a   Lu, Tingting ^a   Pan, Xuebo ^a   Lin, Shaoqiang ^a   Li, Xiaokun ^a,b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b Jilin University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; INSULIN;

ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL;

ADULT; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FEMALE; FIBROBLAST GROWTH FACTORS; GLUCOSE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEALTH; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MATCHED-PAIR ANALYSIS;

ANIMALIA;

EID: 84863579781     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1132     Document Type: Article

References (20)

1. Kharitonenkov A 2009 FGFs and metabolism. Curr Opin Pharmacol 9:805-810
2. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS, Xu A 2008 Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57:1246-1253
3. Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, Matoulek M, Dostalova I, Humenanska V, HaluzikM 2009 Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 71:369-375
4. Stein S, Stepan H, Kratzsch J, Verlohren M, Verlohren HJ, Drynda K, Lössner U, Blüher M, Stumvoll M, Fasshauer M 2010 Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metabolism 59:33-37
5. Chen C, Cheung BM, Tso AW, Wang Y, Law LS, Ong KL, Wat NM, Xu A, Lam KS 2011 High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care 34:2113-2115
6. Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, Zhang H, Pan X, Bao Y, Xiang K, Xu A, JiaW2010 Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 53:934-940
7. Lin Z, Zhou Z, Liu Y, Gong Q, Yan X, Xiao J, Wang X, Lin S, Feng W, Li X 2011 Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS One 6:e18398
8. Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, Xiao J, Wang X, Feng W, Li X 2010 Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One 5:e15534
9. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E 2009 Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 150:4931-4940
10. Yu H, Xia F, Lam KS, Wang Y, Bao Y, Zhang J, Gu Y, Zhou P, Lu J, Jia W, Xu A 2011 Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clin Chem 57:691-700
11. Li H, Bao Y, Xu A, Pan X, Lu J, Wu H, Lu H, Xiang K, Jia W 2009 Serum fibroblast growth factor 21 is associated with adverse lipid profiles and γ-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 94:2151-2156
12. Andersen B, Beck-Nielsen H, Hojlund K 2011 Plasma FGF21 displays a circadian rhythm during a 72-h fast in healthy female volunteers. Clin Endocrinol (Oxf) 75:514-519
13. Chen W, Hoo RL, Konishi M, Itoh N, Lee PC, Ye HY, Lam KS, Xu A 2011 Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes. J Biol Chem 286:34559-34566
14. Krusenstjerna-Hafstrøm T, Madsen M, Vendelbo MH, Pedersen SB, Christiansen JS, Møller N, Jessen N, Jørgensen JO 2011 Insulin and GH signaling in human skeletal muscle in vivo following exogenous GH exposure: impact of an oral glucose load. PLoS One 6:e19392
15. Yang M, Dong J, Liu H, Li L, Yang G 2011 Effects of short-term continuous subcutaneous insulin infusion on fasting plasma fibro-blast growth factor-21 levels in patients with newly diagnosed type 2 diabetes mellitus. PLoS One 6:e26359
16. Berglund ED, Li CY, Bina HA, Lynes SE, Michael MD, Shanafelt AB, Kharitonenkov A, WassermanDH2009 Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 150:4084-4093
17. Fon Tacer K, Bookout AL, Ding X, Kurosu H, John GB, Wang L, Goetz R, Mohammadi M, Kuro-o M, Mangelsdorf DJ, Kliewer SA 2010 Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 24:2050-2064
18. Wente W, Efanov AM, Brenner M, Kharitonenkov A, Köster A, Sandusky GE, Sewing S, Treinies I, Zitzer H, Gromada J 2006 Fibroblast growth factor-21 improves pancreatic β-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55:2470-2478 (Pubitemid 44871147)
19. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA, Tripathy D 2009 Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 32:1542-1546
20. Xiao Y, Xu A, Law LS, Chen C, Li H, Li X, Yang L, Liu S, Zhou Z, Lam KS 2012 Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. J Clin Endocrinol Metab 97:E54-E58